Send to

Choose Destination
Arch Facial Plast Surg. 2011 Jul-Aug;13(4):247-51. doi: 10.1001/archfacial.2011.3. Epub 2011 Feb 21.

Safety, efficacy, and utility of platelet-rich fibrin matrix in facial plastic surgery.

Author information

Division of Facial Plastic and Reconstructive Surgery, The New York Eye and Ear Infirmary, 310 E 14th Street, New York, NY 10003, USA.



To evaluate the clinical safety and efficacy of the use of autologous platelet-rich fibrin matrix (PRFM) in facial plastic surgery.


Medical charts of the last 50 patients with at least 3 months of follow-up who were treated by the author with PRFM for aesthetic purposes were reviewed for patient satisfaction, objective clinical results, and adverse events.


The study cohort of patients was followed up for a mean (SD) of 9.9 (8.0) months (range, 3-30 months). Most patients were treated for deep nasolabial folds, while the volume-depleted midface region, superficial rhytids, and acne scars were other commonly treated areas. The patients underwent an average of 1.6 treatments (range, 1-5 treatments). No patients reported any swelling lasting longer than 5 days, and most noted only minimal bruising lasting for 1 to 3 days. Most patients were satisfied with the results of their treatments, although 1 patient felt that there was limited or no improvement after 2 treatments.


Autologous PRFM treatment is a well-tolerated, excellent choice for use in the face. Further studies on the precise mechanism of action of PRFM are ongoing.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center